Dr Susan Cleator is a Consultant Clinical Oncologist based at Charing Cross Hospital, part of Imperial College Healthcare NHS Foundation Trust.

Dr Cleator trained at Oxford University and Hospitals, and undertook her oncology training at the Charing Cross, Hammersmith, Mount Vernon and The Royal Marsden Hospitals. During this period she also spent three years working full-time on her PhD project at the Institute of Cancer Research and Royal Marsden Hospital. This focused on identifying a molecular assay for predicting the response of breast cancers to chemotherapy. She has published on this and a number of other aspects of oncology.

She works closely with her surgical colleagues at St Mary's hospital where she is responsible for the chemotherapy and radiotherapy aspects of their treatment, specializing in breast, colorectal and lymphomatous cancers. 

Dr Cleator was previously a member of Breast Cancer Studies Group (overseeing Breast Cancer National Research portfolio) and is a member of the American Association Cancer Physicians and the British Medical Association.

Dr Steve Harland is a Consultant Medical Oncologist based at University College London Hospitals NHS Foundation Trust.

Dr Harland trained in medical oncology at the Royal Marsden Hospital following 3 years of research on clinical pharmacology (Hammersmith Hospital) and biochemical pharmacology (Institute of Cancer Research, Sutton). His MD thesis was on mechanisms of resistance to chemotherapy in human tumours. He worked as a senior lecturer in medical oncology for a year in Glasgow before being appointed to the Institute of Urology, UCL

Dr Harland was appointed Senior Lecturer in Medical Oncology at the Institute of Urology in 1986. Since then he has specialised in testis, bladder and prostate cancers and has led on the medical oncological treatment of these tumours at Middlesex and University College Hospitals. 

He has served as Chairman of the MRC Bladder Cancer Group, of the North London Urology Tumour Board and he continues to chair the Castration-resistant Subgroup of the National Cancer Research Network Prostate Cancer Clinical Studies Group. He was on the Editorial Committee of the Government’s document for improving outcomes in urological cancer. He frequently speaks at International meetings.

Dr Samir Agrawal is a Consultant Haematologist based at St Bartholomew's Hospital in London.

Dr Agrawal qualified initially at the University of Bristol subsequently training at The Royal Marsden Cancer Hospitals and being awarded his PhD (in Immunology) at the University of Paris. A former national junior chess champion, Dr Agrawal today is also Director of The Stem Cell Laboratory (at St Bartholomew's) and Head of Diagnostic Immunophenotyping in addition to his consultant and teaching roles.

Dr Agrawal sits on several bodies reviewing outcomes in haemato-oncology, and was a winner of one of the NHS Innovator Awards in 2006 for his work on the introduction of new diagnostic tests for the diagnosis of human leukaemias. A fluent French speaker, he also runs a specialist translation service preparing clinical and scientific medical articles originally written in French for publication in international English/American medical literature.

Dr Paul Nathan is a Consultant Medical Oncologist based at The Mount Vernon Cancer Centre, in Northwood, Middlesex.

Dr Nathan received his first medical degree from Cambridge University and qualified in medicine at University College London, both achieved after earlier degrees (including a PhD) specialising in immunology. He was a Fulbright Scholar and carried out his post-doctoral research at the Pittsburgh Cancer Institute in the US. He initially pursued cancer research in academia and in the pharmaceutical industry before finally deciding to pursue a clinical career.

Dr Nathan has a specialist interest in the treatment of renal cell carcinoma (kidney cancer) and melanoma (both uveal and cutaneous).  He also has an interest in Merkel Cell Carcinoma.

He is first author of the UK guidelines for the systemic treatment of renal cell carcinoma, a member of the National Cancer Research Institute groups for both renal carcinoma and melanoma and is secretary of the UK Melanoma Study Group. He also is a member of the panel currently reviewing the national melanoma guidelines.

Professor Justin Stebbing is a Consultant Medical Oncologist based at Imperial College Healthcare NHS Trust in London.

Professor Stebbing trained in medicine at Trinity College Oxford, where he gained a triple first class degree. After completion of junior doctor posts in Oxford, he undertook a residency at The Johns Hopkins Hospital in the US, returning to London to continue his training in oncology at The Royal Marsden and St Bartholomew’s Hospitals. Professor Stebbing’s PhD research investigated the interplay between the immune system and cancer.

Professor Stebbing has published over 500 peer-reviewed papers in journals such as the Lancet, New England Journal, Blood, the Journal of Clinical Oncology, Annals of Internal Medicine, as well as writing for national newspapers and presenting new data on optimal cancer therapies at major international conferences. His focus is on new therapies in cancer, and the systemic management of patients with a variety of solid malignancies, including a number of new biomarker-based approaches, with an emphasis on circulating tumour cells. His laboratory work is concentrated on new druggable target discovery.

He is a member of the Royal College of Physicians, the American Board of Internal Medicine and the Royal College of Pathologists, and sits on the advisory Boards of five biotechnology companies. He chairs the World Vaccine Congress and is on the editorial board of a number of world leading general medical and cancer journals such as the Journal of Clinical Oncology and Oncogene and writes BMA guidelines for several cancers.

Professor Jamie Cavenagh is a Professor of Haematology based at Barts Health NHS Trust.

Prof Cavenagh qualified with MB BS in 1985 from St Marys Hospital Medical School, London. He trained in clinical haematology at St Georges Hospital, The Royal Marsden Hospital and Barts and The London. 

Professor Cavenagh was a Leukaemia Research Fund Scientific Training Fellow from 1992-1994 and he is currently the Chairman of the UK Myeloma Forum.

Dr Frank Saran is a Consultant Clinical Oncologist based at The Royal Marsden Hospital.

Dr Saran moved to the Marsden in 2001 and is the head of the Neuro-Oncology Unit at The Marsden. Prior to this appointment he worked as a Consultant Clinical Oncologist at Velindre Hospital, Cardiff focussing on the management of primary CNS and spinal cord tumours as well as non-conformal radiotherapy for children with malignant tumours.

His academic and clinical focus is the management of patients requiring complex radiotherapy,conformal high-precision radiotherapy aiming to maximise tumour control while minimising the risk of potential long term side effects as well as novel systemic therapy approaches in primary CNS tumours. 

Dr Saran is regularly invited to give lectures on his subjects of expertise both internationally and nationally. He is member of many societies and national working groups including ESTRO, RCR, CCLG, NCRI Paediatric CNS tumour group and SIOP-E Brain Tumour Working Group.

Dr David Propper is a Consultant Medical Oncologist based at Barts and The London NHS Trust.

Dr Propper trained in medical oncology at the Imperial Cancer Research Fund Medical Oncology Unit in Oxford and received major trial research experience there. He subsequently spent time at the Lombardi Cancer Centre Georgetown Washington DC, USA.

Dr Propper has interests in translational research, early phase trials and the introduction of new therapeutic agents.

Dr David Landau is a Consultant Clinical Oncologist at Guys and St. Thomas' NHS Trust.

Dr Landau qualified at Charing Cross and Westminster Medical School (now part of Imperial) in 1990. Most of his training in Clinical Oncology was at Charing Cross Hospital and he finished his training with clinical and research posts at The Royal Marsden Hospital.

Dr Landau now specialises only in cancers of the thorax, lung cancers, mesothelioma and thymoma. He also has a specialist interest in metastatic disease from many primaries. He has a particular interest in high-tech radiotherapy treatments.

Dr Landau is one of one founders of London Oncology Clinic in Harley Street and speaks English and French.

Dr Chris Cottrill is a Consultant Clinical Oncologist based at Barts Cancer Centre (St Bartholomews Hospital) in London.

Dr Cottrill specialises in Breast and Gastrointestinal (oesophagus, stomach, pancreas, colon, rectum and anus) cancers and has a specialist interest in stereotactic radiosurgery (CyberKnife treatment). He has a particular interest in combined modality therapy (combination chemo-radiotherapy). He has been a Consultant at St Bartholomew's Hospital for 10 years and is experienced in all aspects of the chemotherapy and radiotherapy treatment of Breast and Gastrointestinal cancers.

Within the field of radiotherapy Dr Cottrill has a specialist interest in combined chemo-radiotherapy, intensity-modulated radiotherapy (IMRT, RapidArc, VMAT) and image-guided radiotherapy (IGRT). He is fully accredited in the use of CyberKnife stereotactic ablative radiotherapy (SABR) at Barts Hospital, the London Clinic and the Harley Street Clinic CyberKnife units.

Since 2000 Dr Cottrill has lectured annually on international postgraduate courses in the field of evidence-based radiation therapy for the European Society for Radiotherapy and Oncology (ESTRO).